Alexion Pharmaceuticals Employees 2024

Alexion Pharmaceuticals Aktienanalyse

What does Alexion Pharmaceuticals do?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Alexion Pharmaceuticals revenue by segment

In the annual report of the Alexion Pharmaceuticals share (US0153511094, 899527, ALXN), it breaks down its revenues into 1 segments: 1. Therapies. The Alexion Pharmaceuticals stock (WKN: 899527, ISIN: US0153511094, Ticker Symbol: ALXN) is a leading investment for investors interested in participating in the Health Care sector.

Employees Details

Examining Alexion Pharmaceuticals's Employee Base

Alexion Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Alexion Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Alexion Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Alexion Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Alexion Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Alexion Pharmaceuticals Stock

How many employees does Alexion Pharmaceuticals have this year?

Alexion Pharmaceuticals has 0 undefined employees this year.

How many employees did Alexion Pharmaceuticals have compared to the previous year?

Compared to the previous year, Alexion Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Alexion Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Alexion Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Alexion Pharmaceuticals?

The number of employees can also have an impact on investors of Alexion Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Alexion Pharmaceuticals affect the company?

An increase in equity of Alexion Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Alexion Pharmaceuticals's equity affect the company?

A reduction in equity of Alexion Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Alexion Pharmaceuticals?

Some factors that can influence the equity of Alexion Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Alexion Pharmaceuticals so important for investors?

The equity of Alexion Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Alexion Pharmaceuticals influence the company?

The number of employees at Alexion Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Alexion Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Alexion Pharmaceuticals has changed by NaN.

How many employees does Alexion Pharmaceuticals currently have?

Alexion Pharmaceuticals currently has 0 undefined employees.

Why is the number of employees important for investors of Alexion Pharmaceuticals?

The number of employees is important for investors of Alexion Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Alexion Pharmaceuticals take to change the number of employees?

To change the number of employees, Alexion Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Alexion Pharmaceuticals pay?

Over the past 12 months, Alexion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alexion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alexion Pharmaceuticals?

The current dividend yield of Alexion Pharmaceuticals is .

When does Alexion Pharmaceuticals pay dividends?

Alexion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alexion Pharmaceuticals?

Alexion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alexion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alexion Pharmaceuticals located?

Alexion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alexion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alexion Pharmaceuticals from 4/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/20/2024.

When did Alexion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/20/2024.

What was the dividend of Alexion Pharmaceuticals in the year 2023?

In the year 2023, Alexion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alexion Pharmaceuticals pay out the dividend?

The dividends of Alexion Pharmaceuticals are distributed in USD.